Intervention Review

Tongxinluo capsule for acute stroke

  1. Qi Zhuo2,
  2. Xunzhe Yang2,
  3. Taixiang Wu1,*,
  4. Guanjian Liu1,
  5. Likun Zhou3

Editorial Group: Cochrane Stroke Group

Published Online: 8 OCT 2008

Assessed as up-to-date: 18 MAR 2008

DOI: 10.1002/14651858.CD004584.pub2

How to Cite

Zhuo Q, Yang X, Wu T, Liu G, Zhou L. Tongxinluo capsule for acute stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD004584. DOI: 10.1002/14651858.CD004584.pub2.

Author Information

  1. 1

    West China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese EBM Centre, Chengdu, Sichuan, China

  2. 2

    Sichuan University, West China Hospital, Chengdu, Sichuan, China

  3. 3

    West China Hospital of Sichuan University, Clinical Epidemiology, Chengdu, Sichuan Province, China

*Taixiang Wu, Chinese Cochrane Centre, Chinese EBM Centre, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. txwutx@hotmail.com. txwutx@public.cd.sc.cn.

Publication History

  1. Publication Status: New
  2. Published Online: 8 OCT 2008

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Tongxinluo capsules are a compound of Chinese traditional medicine which contain substances that are thought to have vasodilatory, antiplatelet, anticoagulant, thrombolytic and even lipid-lowering properties, and therefore may improve outcome after acute ischaemic stroke. To date the evidence of its effect has not been systematically reviewed, making it difficult to derive robust conclusions about its actual benefits, and indeed, possible harms.

Objectives

To assess the effectiveness and possible harms of tongxinluo capsule for acute cerebral infarction compared with control.

Search methods

We searched the Cochrane Stroke Group trials register (last searched on 24 January 2008) the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2007), MEDLINE (1995 to 2006), EMBASE (1995 to 2006), China National Knowledge Infrastructure (CNKI, 1994 to 2006), CBM (Chinese Biomedical Database) (1995 to 2006), Current Controlled Trials (www.controlled-trials.com), National Research Register (http://www.update-software.com/national/). We handsearched 30 journals (1995 to 2006), and contacted drug companies and the principal of included trials.

Selection criteria

Randomised controlled trials comparing tongxinluo with placebo or open control (or tongxinluo plus standard therapy versus standard therapy alone) in people with definite acute stroke. We excluded trials if they sought to recruit patients with transient ischaemic attacks (TIA), intracerebral haemorrhage, heart failure, or renal failure.

Data collection and analysis

Two review authors extracted data and assessed trial quality.

Main results

Only two poor quality studies with a total of 232 participants were included in this review. Neither study reported any of our pre-specified outcomes, so no reliable estimate of the effect of treatment on major clinical outcomes could be obtained.

Authors' conclusions

It was not possible to reliably determine whether tongxinluo has a favourable or unfavourable effect in acute ischaemic stroke. High quality trials are required to assess the efficacy and safety of tongxinluo capsule for acute ischaemic stroke.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Tongxinluo capsule for acute stroke

Traditional Chinese medicine is often used to treat patients with acute ischaemic stroke. The authors undertook a systematic review of the potential benefits and safety of tongxinluo capsule used for the treatment of patients with acute ischaemic stroke. Two relevant studies with a total of 232 participants were identified, but they did not provide reliable evidence about the effects of this treatment. Larger-scale high quality randomised controlled trials (RCTs) are needed to determine the effects of tongxinluo capsule in patients with stroke.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

以Tongxinluo(通心絡)膠囊治療急性腦中風

Tongxinluo膠囊是一種複方中藥,其內含的物質被認為有擴張血管,抗血小板,抗凝血,溶解血栓,甚至降低血脂肪的特性,因此也許能改善急性缺血性中風的癒後。到目前為止,其療效的證據尚未被系統性地回顧,因此對於它實際的益處難以得到可靠的結論,而且事實上,可能有害。

目標

為了評估Tongxinluo膠囊相較於對照組,於急性腦梗塞的療效和可能的危害。

搜尋策略

我們搜尋了Cochrane Stroke Group trials register(2008年1月24日最後一次搜尋)、Cochrane Central Register of Controlled Trials (CENTRAL)(The Cochrane Library,Issue 4,2007)、MEDLINE(1995年至2006年)、EMBASE(1995年至2006年)、China National Knowledge Infrastructure(CNKI,1994年至2006年)、CBM(Chinese Biomedical Database)(1995年至2006年)、Current Controlled Trials(www.controlledtrials.com)、National Research Register(http://www.updatesoftware.com / national /)。我們親手搜尋了30種期刊(1995年至2006年),並與製藥公司和被納入試驗之主導者取得聯繫。

選擇標準

比較使用Tongxinluo與安慰劑或開放對照(或比較Tongxinluo加上標準療法與單用標準療法)於確定為急性中風患者之隨機對照試驗。如果試驗試圖納入暫時性腦缺血(TIA)、腦內出血、心臟衰竭或腎臟衰竭的患者,我們便排除此試驗。

資料收集與分析

兩位回顧作者擷取數據並評估試驗品質。

主要結論

這篇回顧論文只包含了兩個品質較差的研究,共有232位受試者。沒有研究報告任何我們預先指定的結果,因此對於主要臨床結果的治療成效無法得到可靠的估計。

作者結論

要可靠地確定是否Tongxinluo於急性缺血性中風存在有利或有害的效果是不可能的。需要高品質的試驗來評估Tongxinluo膠囊於急性缺血性中風治療的效果和安全性。

翻譯人

本摘要由奇美醫院張偉倫翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

以Tongxinluo膠囊治療急性中風:傳統中藥常被用於治療急性缺血性中風的病人。作者進行了對於Tongxinluo膠囊使用於治療急性缺血性中風病人的潛在益處和安全性的系統性回顧。作者發現了兩個相關的研究,共有232位受試者,但這些研究無法提供關於這種治療之效果的可靠證據。我們需要更大規模的高品質的隨機對照試驗(RCTs)來確定Tongxinluo膠囊於中風病人的療效。